AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Compared to Estimates, Astrazeneca (AZN) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AstraZeneca's strong U.S. ties reflect Trump's policy of equalization, says CEO
AstraZeneca CEO Pascal Soriot discusses Q3 earnings and the pharma giant's relationship with the U.S. administration.
AstraZeneca grows faster than expected but maintains guidance
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted a confident set of third-quarter results, not only beating revenue and core earnings forecasts, but also hailing "strong underlying momentum" across the business to set up growth through next year as well. The FTSE 100 pharmaceutical group generated revenues of $15.19 billion in the three months to 30 September, up 12% compared to a year ago and beating the consensus forecast of $14.8 billion.
AstraZeneca beats third-quarter revenue and profit expectations
AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney disease drugs, prompting London's most valuable listed company to retain its full-year forecasts.
AstraZeneca wins shareholder backing for NYSE listing in US pivot
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
AstraZeneca to face questions on Trump MFN deal, patent expiries and pipeline
When AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) reports third-quarter results next Thursday, 6 November, with investors and analysts will be keen to hear about the financial implications of the 'most favoured nation' (MFN) pricing deal recently agreed with Donald Trump, as well as the loss of its Farxiga patent and prospects for new drugs coming out of its pipeline. This will be the first opportunity for discussion of the US MFN deal, making its a key discussion point, according to analysts at UBS.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
Astrazeneca (AZN) closed at $82.61 in the latest trading session, marking a -1.72% move from the prior day.
AstraZeneca found in breach of industry code over Symbicort marketing, industry body says
AstraZeneca breached the UK pharmaceutical industry's code of practice by using a claim that misleadingly implied its Symbicort asthma drug was suitable for all newly diagnosed patients aged 12 years and over, the industry self-regulatory body ruled on Friday.
AstraZeneca's Datroway extends survival in aggressive breast cancer
AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat forms of the disease.
AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment
AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.
AstraZeneca downgraded by leading investment bank. Here's why
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) investors might want to take a deep breath. Deutsche Bank has turned bearish on the UK drugmaker, cutting its rating from Hold to Sell and trimming its price target to £105 from £110, well below the current share price of 12,548p (down 1%).
